Drugs / Fedovapagon
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02537288 | Oct → Dec 2015 | — | Vantia Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02440841 | May → Jul 2015 | — | Vantia Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01656239 | Aug 2012 → Aug 2013 | — | Vantia Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02637960 | Mar 2016 → Jul 2017 | nocturnal enuresis | Vantia Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fedovapagon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02537288 ↗ |
| Action | Activate | “Fedovapagon is a selective vasopressin V2 receptor (V2 receptor) agonist” NCT01656239 ↗ |
| Route | Oral | “Once daily oral dose of 1 mg fedovapagon for 12 weeks” NCT01656239 ↗ |